logo-loader
viewFrontier IP Group PLC

Frontier IP moves into vaccines with latest addition to the investment portfolio

It is taking a 21% stake in The Vaccine Group, a spinout company from the University of Plymouth

birds against a sunset
Initial work will focus on platforms that prevent the spread of pathogens from animals to people such as avian flu

The AIM-listed incubator company Frontier IP Group Plc (LON:FIPP) has added a new investment to its portfolio.

It is taking a 21% stake in The Vaccine Group, a spinout company from the University of Plymouth.

In return it will provide commercialisation services, industry expertise and “strong links” to the pharmaceutical sector.

Paul Mantle, a portfolio executive at Frontier, is already director of  the fledgling business and brings with him expertise in commercialising new technology.

The new company was set up to exploit advances in immunology developed by Dr Michael Jarvis, associate professor in Virology and Immunology at Plymouth, who specialises in the creative design of herpesvirus-based vaccines for the control of disease.

Breaking the human barrier

Initial work will focus on platforms that prevent the spread of pathogens from animals to people.

Research will be carried out into avian influenza A, Ebola and Marburg viruses, MERS and SARS coronaviruses and Rift Valley fever virus.

“Emerging infectious diseases are a growing threat to economies and to the global population,” said Frontier chief executive Neil Crabb.

“A rapid response vaccine platform will be a valuable addition to current management strategies and a critical resource when new diseases emerge."

Quick facts: Frontier IP Group PLC

Price: 75.5 GBX

AIM:FIPP
Market: AIM
Market Cap: £41.53 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Frontier IP Group PLC named herein, including the promotion by the Company of Frontier IP Group PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Frontier IP Group teams up with University of Cambridge to tackle gum disease

Frontier IP Group PLC's (LON:FIPP) Neil Crabb discusses with Proactive London's Andrew Scott a new joint project between themselves and the University of Cambridge to tackle gum disease. The study's received a £52,891 grant from the National Biofilms Innovation Centre (NBIC). The...

on 19/6/20

2 min read